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doi:10.1016/j.ejvs.2010.07.013Abstract Objectives: The purpose of this study was to evaluate the utility of B-type natri-
uretic peptide (BNP) to predict blood pressure (BP) response in patients with renal artery
stenosis (RAS) after renal angioplasty and stenting (PTRA).
Methods: In 120 patients with RAS and hypertension referred for PTRA, 24-h ambulatory BP
recordings were obtained before and 6 months after intervention. BNP was measured before,
1 day and 6 months after PTRA.
Results: BP improved in 54% of patients. Median BNP levels pre-intervention were 97 pg ml1
(interquartile range (IQR) 35e250) and decreased significantly within 1 day of PTRA to
62 pg ml1 (IQR 24e182) (p < 0.001), remaining at 75 pg ml1 (IQR 31e190) at 6 months.
The area under the receiver operating curve for pre-intervention BNP to predict BP
improvement was 0.57 (95% confidence interval (CI) 0.46e0.67). Pre-intervention BNP
>50 pg ml1 was seen in 79% of patients with BP improvement compared with 56% in
patients without improvement (p Z 0.01). In a multivariate logistic regression analysis,
BNP >50 pg ml1 was significantly associated with BP improvement (odds ratio (OR) 4.0,
95% CI 1.2e13.2).265 58 26; fax: þ41 61 265 5353.
h (C. Mueller).
lly to this work.
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600 D. Staub et al.Conclusions: BNP levels are elevated in patients with RAS and decrease after revascularisa-
tion. Although BNP does not seem useful as a continuous variable, pre-interventional BNP
>50 pg ml1 may be helpful to identify patients in whom PTRA will improve BP.
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secondary arterial hypertension by means of inducing the
renineangiotensin system, volume expansion and sympa-
thetic activation.1 The use of renal angioplasty and stenting
(PTRA) for RAS in patients with renovascular hypertension
has become increasingly more common.2 Despite high
technical success and low restenosis rates, large observa-
tional studies and controlled trials have consistently shown
that only about 60% of patients show improvement in BP
after revascularisation of RAS.3e5 The accurate prediction
of achievable BP control, and therefore, selection of
patients, which would undoubtedly benefit from revascu-
larisation, is a major unmet clinical need.
B-typenatriuretic peptide (BNP)maybean ideal biomarker
to identify those patients who benefit the most from correc-
tion of RAS. BNP is a neurohormone synthesised and released
predominantly from left and right ventricular myocytes in
response to ventricular stretch in the setting of volume
expansion or pressure overload and neurohormonal activa-
tion.6 BNP is a well-established marker of congestive heart
failure and the measurement of BNP is helpful in the emer-
gency diagnosis of patients with acute dyspnoea.7 Up-regula-
tion of BNP has also been demonstrated in animal models and
in patients with renovascular hypertension.8,9 In vitro data
suggest that Angiotensin II is able to induce BNP gene expres-
sion independent of myocardial stretch.10 In a recent pilot
study of selected patientswith severe atherosclerotic RAS and
refractory hypertension, referred for further treatment by
means of renal artery revascularisation, BNP was shown to be
useful in the prediction of BP response post-intervention.11
The aim of this study was to evaluate the utility of BNP levels
to predict BP response in unselected patients with significant
RAS and arterial hypertension referred for PTRA.
Methods and Methods
Patient population
This prospective two-centre study included consecutive
patients undergoing PTRA for RAS from August 2004 to
December 2007 at the University Hospital Basel, Switzerland,
and the Herz-Zentrum Bad Krozingen, Germany. Indications
for renal arterial endovascular treatment were unilateral or
bilateral RAS 50% and arterial hypertension (systolic BP
140 mmHg and/or diastolic BP 90 mmHg or on any anti-
hypertensive drug therapy). Assessment of RAS was based
primarily on duplex ultrasound using a Philips ATL, HDI 5000
(Philips, Best, the Netherlands). As described previously, RAS
was classified as haemodynamically relevant if the renal/
aortal velocity ratio was 2.5.12 For unilateral RAS, the side-
to-side difference in intrarenal resistance index (RI Z 1 e
(end-diastolic velocity/peak systolic velocity)) between the
twokidneys>0.05wasalsousedtoclassifyhaemodynamically
relevant RAS. Before intervention, duplex ultrasound wasalways confirmed by intra-arterial angiography showing
a percent diameter stenosis 50% by measuring the ratio
between the diameter of the narrowest segment of the
imaged renal artery and the diameter of a normal segment of
the artery proximal to the stenosis or distal to poststenotic
dilation. Alternatively, an intra-arterial, translesional systolic
pressure gradient of 20 mmHg was considered as haemody-
namically relevant and was assessed in 31 patients.12 A RAS
70%was documented in 87% of all patients andmean systolic
pressure gradient was 72  46 mmHg. Lesions were cat-
egorised as artherosclerotic or fibromuscular dysplasia.
The study was carried out according to the principles of
the Declaration of Helsinki and approved by the local ethics
committees. Written informed consent was obtained from
all participating patients.
Revascularisation procedure
For atherosclerotic renal artery lesions, a stent placement
procedure with and without predilatation using a guiding
catheter technique via the femoral access and a variety of
balloon-expandable renal stents were used, such as Hip-
pocampus (Invatec), Dynamic renal (Biotronik) or Pal-
maz blue (J&J Cordis). In patients with fibromuscular
dysplasia, the lesion was dilated with an angioplasty
balloon catheter without stent placement. Procedural
success was defined as <30% residual luminal narrowing or
residual peak translesional pressure gradient <10 mmHg.
Anti-platelet therapy was started at least 1 day before the
intervention and routinely consisted of 75 mg of clopidogrel
daily for 4 weeks and 100 mg of aspirin indefinitely.
Follow-up and definitions
Baseline evaluation before PTRA and follow-up examina-
tions 6 months after the revascularisation procedure
included duplex ultrasound with measurement of the renal/
aortal velocity ratio and intrarenal RI, measurement of
serum creatinine, 24-h ambulatory BP monitoring (BSI,
SpaceLab Medical Inc., Issaquah, WA, USA) and documen-
tation of anti-hypertensive drugs.
Two patients died during the follow-up period and five
patients refused follow-up examination after PTRA (Fig. 1).
Therefore, follow-up data regarding BP at 6 months were
available from 120 patients (95%). Improvement in BP 6
months after PTRA was predefined as either clinical cure
(systolic BP <140 mmHg and diastolic pressure <90 mmHg
during 24-h BP monitoring, while receiving no anti-hyper-
tensive medications) or clinical benefit in BP.13 The criteria
for a measurable clinical benefit included: (1) a decrease in
mean arterial pressure of 5 mmHg on the same or reduced
number of anti-hypertensive medications as before PTRA,
or (2) no appreciable change in mean arterial pressure
(decrease of less then 5 mmHg) and a reduction in one or
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Figure 1 Flow diagram of patients with renal artery stenosis
referred for revascularization.
Natriuretic Peptide and Renal Artery Stenosis 601more medications from baseline on mean 24-h BP. Clinical
failure was defined as receiving no benefit from PTRA (that
is, not fitting into any of the afore-mentioned classifica-
tions), as well as having to increase the number of anti-
hypertensive medications from baseline, or finding an
increase in mean arterial pressure at 6 months follow-up.
Blood sampling and laboratory methods
A specimen of venous blood for BNPmeasurement was drawn
before the intervention, 1 day and 6 months after the
intervention. These samples were collected in plastic tubes
containing ethylene diamine tetraacetic acid (EDTA) and
were centrifuged at 3000 g and analysed immediately. BNP
concentration was determined using the commercially
available Biosite assay (Biosite Diagnostics, La Jolla, CA,
USA). Precision, analytical sensitivity and stability charac-
teristics of this fluorescence immunoassay have been previ-
ously described.14 In brief, the coefficient of variation for
intra-assay precision has been reported to be 9.5%, 12.0% and
13.9%, and the coefficient of variation for interassay preci-
sion is known to be 10.0%, 12.4% and 14.8% for BNP levels of
28.8, 584.0 and 1180.0 pg ml1, respectively. The analytic
sensitivity was <5.0 pg ml1, with a measurable range of
0e5000 pg ml1. As previously described, age- and gender-
specific median levels (25th and 75th percentiles) of plasma
BNP using the same Biosite assay in 767 normal subjects in
sinus rhythmus without cardiovascular disease or cardiac
dysfunctionwere 27 (15, 43) pgml1 and11 (5, 20) pgml1 for
women and men of 55e64 years of age, and 29 (19, 52)
pg ml1 and 18 (7, 37) pg ml1 for women and men of 65e74
years of age, respectively.15
The laboratory technician who measured BNP was blin-
ded to patient information. To estimate the glomerular
filtration rate (eGFR), we used the formula for creatinine
clearance calculated by the abbreviated Modification of
Diet in Renal Disease Study equation.16Statistical analysis
The primary objective of this study was to examine whether
pre-interventional BNP levels predicted improvement in BP
by the 6 month follow-up end point.
Statistical analyses were performed using SPSS/PC
(version 15.0, SPSS Inc., Chicago, IL, USA). Discrete vari-
ables were expressed as numbers and percentages,
continuous variables as mean  SD or median and inter-
quartile range (25th to 75th percentiles) when the sample
data was not normally distributed. Univariate analysis of
patients with BP improvement compared to patients
without BP improvement were made using analysis of
variance (ANOVA) or ManneWhitney U test for continuous
factors as appropriate and chi-square tests for categorical
factors. Area under the receiver operating characteristic
curve was used to estimate the optimal cut-off of baseline
BNP and decrease in BNP for the prediction of BP
improvement. Multivariable logistic regression analyses
were performed to assess the association of BP improve-
ment with pre-intervention BNP >50 pg ml1 (adjusted for
age, sex, pre-intervention mean arterial pressure, eGFR
<60 ml min1 1.73 m2, and intrarenal RI).Results
Baseline characteristics and renal artery
intervention
The baseline clinical characteristics are shown in Table 1.
Haemodynamically relevant bilateral stenosis was found in
13 patients (11%). The majority of all lesions were athero-
sclerotic ostial stenoses (77%). RAS due to fibromuscular
dysplasia was documented in 17 patients (14%). The
primary technical success rates for renal revascularisation
were 100%.
There was no procedure-related death. Two patients
died from acute myocardial infarction during the follow-up
period (Fig. 1). We observed four major procedural
complications: intrarenal bleeding successfully treated
with embolisation; acute occlusion of the main renal artery
1 week after stent implantation with spontaneous re-
opening; perforation of the main renal artery treated with
extended balloon dilation; and dissection of main renal
artery distal from stent implantation with occlusion of
a segmental arterial branch.
BP response
As shown in Table 1, mean systolic and diastolic BP
decreased from baseline values of 148  17 and
81  13 mmHg before intervention to 137  16 and
77  11 mmHg after renal angioplasty at the 6 month
follow-up (p < 0.001 for both). The number of anti-hyper-
tensive agents significantly decreased from 2.9  1.3 to
2.6  1.4 (pZ 0.009). BP improvement was documented in
54% of patients (65/120 patients). Three patients had
a clinical cure of BP and 62 patients met the criteria for
clinical benefit in BP. Differences in baseline characteristics
between patients with and without BP improvement are
Table 1 Baseline characteristics of consecutive patients undergoing renal artery revascularization with and without blood
pressure improvement during follow up.
All patients
(n Z 120)
Patients with
BP-improvement
(n Z 65)
Patients without
BP-improvement
(n Z 55)
P-value
Age, y 63  13 62  14 65  12 0.11
Male sex, n (%) 62 (52) 33 (51) 29(53) 0.83
Diabetes mellitus, n (%) 19 (16) 11 (17) 8 (15) 0.67
Hypercholesterolemia, n (%) 88 (73) 44 (68) 44 (80) 0.15
Smoker, n (%) 50 (42) 28 (43) 22 (40) 0.58
Co-morbidities:
CAD, n (%) 44 (37) 25 (38) 19 (35) 0.62
PAD, n (%) 43 (36) 22 (34) 21 (38) 0.67
LVEF <40%, n (%) 6 (5) 3 (5) 3 (5) 0.89
Baseline eGFR, ml/min/1.73 m2 66  28 64  31 67  24 0.60
Follow-up eGFR, ml/min/1.73 m2 69  29y 69  33y 68  24 0.84
Basline eGFR < 60 ml/min/1.73 m2, n (%) 52 (43) 32 (51) 20 (36) 0.11
Arterial hypertension:
Refractory hypertension, n (%) 30 (25) 16 (25) 14 (25) 0.92
SBP at baseline, mmHg 148  17 153  16 141  16 <0.001
DBP at baseline, mmHg 81  13 84  11 77  14 0.003
MAP at baseline, mmHg 103  13 107  11 98  13 <0.001
SBP at follow-up, mmHg 137  16* 132  15* 142  17 0.002
DBP at follow-up, mmHg 77  11* 74  9* 79  12 0.02
MAP at follow-up, mmHg 97  11* 94  9* 100  13 0.005
Number of anti-hypertensive drugs at baseline 2.9  1.3 2.8  1.3 3.0  1.3 0.38
ACE inhibitor or ARB at baseline, n (%) 80 (67) 43 (66) 37 (67) 0.91
Number of anti-hypertensive drugs at follow-up 2.6  1.4y 2.2  1.4* 3.0  1.3 0.006
Renal anatomy and physiology:
Kidney length, mm 103  13 102  12 104  14 0.36
Renal/aortal ratio at baseline 5.2  1.9 5.6  1.9 4.9  1.8 0.12
Intrarenal RI at baseline 0.63  0.10 0.61  0.10 0.64  0.08 0.07
Bilateral stenosis, n (%) 13 (11) 9 (14) 4 (7) 0.25
70% stenosis, n (%) 104 (87) 59 (91) 45 (82) 0.15
Ostial stenosis, n (%) 92 (77) 46 (71) 46 (84) 0.06
Stent placed, n (%) 102 (85) 52 (80) 50 (91) 0.09
Fibromuscular dysplasia, n (%) 17 (14) 14 (22) 3 (5) 0.01
BP indicates blood pressure; CAD, coronary artery disease; PAD, peripheral artery disease; LVEF, left ventricular ejection fraction, eGFR,
estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; ACE,
angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; RI, resistive index. Data are expressed as mean  SD, or number
(percentage) of patients. *P < 0.001 compared with baseline, yP < 0.05 compared with baseline.
602 D. Staub et al.shown in Table 1. Factors significantly associated with BP
improvement were elevated BP at baseline and fibromus-
cular dysplasia.
Angiographic imaging and clinical course of two typical
cases are shown in Fig. 2.BNP measurements in patients with and without BP
improvement
Median BNP before revascularisation was 97 pg ml1 (IQR
35e250) and decreased significantly within 1 day after
PTRA to 62 pg ml1 (IQR 24e182) (p < 0.001), remaining at
75 pg ml1 (IQR 31e190) at the 6 month follow-up (pZ 0.02
compared to pre-intervention). BNP levels at baseline,
after revascularisation and 6 months’ post procedure are
shown in Table 2 and Fig. 3. To note, there was a trendtowards increase in BNP from day 1e6 months after inter-
vention in both groups in spite of sustained successful
revascularisation of RAS.
The area under the receiver operating curve for the
ability to predict BP improvement was 0.57 (95% confidence
interval (CI) 0.46e0.67) for pre-intervention BNP and 0.56
(95% CI 0.45e0.87) for decrease in BNP 1 day after revas-
cularisation. The most accurate cut-offs for pre-interven-
tion BNP and decreases in BNP were 50 pg ml1 and
20 pg ml1, respectively.
Pre-intervention BNP levels of >50 pg ml1 were docu-
mented in 82 patients (68%) and were significantly associ-
ated with BP improvement (Table 2). In patients with BNP
levels >50 pg ml1, BP improvement occurred in 62% of
patients compared with 37% of patients with a pre-inter-
vention BNP 50 pg ml1 (pZ 0.01) (Fig. 4). The sensitivity
and specificity of using a pre-intervention BNP >50 pg ml1
Figure 2 Angiographic imaging of renal artery stenosis in two typical cases. Panel A. Ostial atherosclerotic renal artery stenosis
(arrow) in a 55-year old woman. The patient had blood pressure improvement (decrease in mean arterial pressure of 10 mmHg) six
month after successful renal artery stent placement (panel B) (arrows). BNP level before revascularization was 80 pg/ml and
decreased within one day of intervention to 50 pg/ml. Panel B. Renal artery fibromuscular dysplasia showing characteristic ‘string-
of-beads’ appearance (arrow) in a 59-year old woman. The patient had blood pressure improvement (clinical cure) six month after
angioplasty. BNP level before revascularization was 89 pg/ml and decreased within one day of intervention to 49 pg/ml.
Table 2 B-type natriuretic peptide levels in patients with and without blood pressure improvement during follow up.
BNP levels All patients Patients with
BP-improvement
Patients without
BP-improvement
P-value
Overall cohort (n Z 120) (n Z 65) (n Z 45)
BNP pre-intervention, pg/ml 97 (35, 250) 109 (53, 259) 68 (25, 237) 0.20
BNP >50 pg/ml pre-intervention, n (%) 82 (68) 51 (79) 31 (56) 0.01
BNP 1 day post-intervention, pg/ml 62 (24, 182)* 71 (21, 181)* 50 (24, 210)y 0.74
BNP decrease >20 pg/ml, n (%) 57 (47) 37 (59) 20 (39) 0.04
BNP 6 months post-intervention, pg/ml 75 (31, 190)y 89 (38, 191)y 63 (24, 199) 0.75
Patients with 70% atherosclerotic RAS (n Z 91) (n Z 48) (n Z 43)
BNP pre-intervention, pg/ml 109 (39, 265) 125 (55, 288) 95 (23, 237) 0.15
BNP >50 pg/ml pre-intervention, n (%) 65 (71) 40 (83) 25 (58) 0.008
BNP 1 day post-intervention, pg/ml 67 (24, 216)* 77 (31, 216)* 54 (24, 217)y 0.58
BNP decrease >20 pg/ml, n (%) 44 (48) 28 (58) 16 (37) 0.09
Patients with refractory hypertension (n Z 30) (n Z 16) (n Z 14)
BNP pre-intervention, pg/ml 119 (52, 305) 145 (73, 288) 59 (21, 405) 0.15
BNP >50 pg/ml pre-intervention, n (%) 23 (77) 16 (100) 7 (50) 0.001
BNP 1 day post-intervention, pg/ml 70 (34, 280)y 144 (41, 287) 54 (27, 290) 0.36
BNP decrease >20 pg/ml, n (%) 15 (50) 9 (56) 6 (43) 0.59
BNP indicates B-type natriuretic peptide; BP, blood pressure; RAS, renal artery stenosis. Data are expressed as median (25th and 75th
percentiles), or number (percentage) of patients. *P < 0.001 compared with BNP pre-intervention, yP < 0.05 compared with BNP pre-
intervention.
Natriuretic Peptide and Renal Artery Stenosis 603
)952,35(901
)181,12(17
)191,83(98
)732,52(86
)012,42(05
)991,42(36
0
02
04
06
08
001
021
1 day post-intervention 6 months post-interventionPre-intervention
B
-
t
y
p
e
 
n
a
t
r
i
u
r
e
t
i
c
 
p
e
p
t
i
d
e
,
 
p
g
/
m
L
Patients without blood pressure improvement
Patients with blood pressure improvement
†
*
†
Figure 3 Median (25th to 75th percentiles) BNP levels before
and after percutaneous revascularization for renal artery
stenosis in patients with and without blood pressure improve-
ment. *P < 0.001 compared to BNP levels pre-intervention,
yP < 0.05 compared to BNP levels pre-intervention.
604 D. Staub et al.to predict BP improvement at the 6-month follow-up were
79% and 44%, respectively (Table 3).
A decrease in BNP >20 pg ml1 1 day after the inter-
vention was revealed in 57 patients (47%) and was also
significantly associated with BP improvement (Table 2). In
patients with a decrease in BNP >20 pg ml1, BP improve-
ment occurred in 65% of patients compared with 46% of
patients with a decrease in BNP 20 pg ml1 (p Z 0.04)
(Fig. 4).
As shown in Table 4, multivariate logistic regression
analysis shows that elevated pre-intervention BNP levels
>50 pg ml1, adjusted for age, sex, pre-interventional
mean arterial pressure, eGFR < 60 ml1 min1 1.73 m2 and
intrarenal RI, was significantly associated with BP
improvement (odds ratio (OR) 4.0, 95% CI 1.2e13.2).
Subgroup analysis
After exclusionofpatientswithconditionsother thanRAS that
might increase BNP, including congestive heart failure (left0
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Figure 4 Percent of patients with blood pressure
improvement 6 month after percutaneous revascularization
for renal artery stenosis. Pre-intervention BNP >50 pg/ml vs
pre-intervention BNP 50 pg/ml, and BNP decrease 1 day
after intervention >20 pg/ml vs BNP decrease 20 pg/ml.ventricular ejection fraction < 40%) and chronic renal insuf-
ficiency (elevated baseline creatinine  177 mmol l1) from
the analysis, the diagnostic performance was similar. Sensi-
tivity and specificity of using a pre-intervention
BNP> 50 pg ml1 to predict BP improvement in this subgroup
were 75% and 48%, respectively. Higher diagnostic perfor-
mance was found in 91 patients with 70% atherosclerotic
RAS,and thehighest sensitivity of 100%anda specificity of 50%
were found in selected 30 patients with refractory hyper-
tension (pre-interventional BP that could not be reduced to
<140/90 mmHg with a three-drug regimen) (Table 3).Discussion
This prospective study in unselected consecutive patients
with haemodynamically relevant RAS and arterial hyper-
tension referred for PTRA, evaluated the utility of BNP
levels to predict BP improvement after successful revas-
cularisation. One of the important strengths of our study
design was that the BP response was quantified using 24-h
ambulatory BP recordings. We report five major findings.
First, pre-interventional BNP is elevated in most patients
with RAS and decreases significantly 1 day after revascu-
larisation supporting the pathophysiological concept that
haemodynamically significant RAS causes elevations in BNP.
Second, although BNP shows poor accuracy in the predic-
tion of BP response when used as a continuous variable, in
a multivariate analysis, BNP levels above 50 pg ml1 before
intervention was the strongest predictor and increased the
chance of BP improvement at 6 months fourfold, indepen-
dent of clinical and duplex sonographic parameters. In this
analysis, prediction of BP response based on age and pre-
interventional mean arterial pressure was less pronounced
than BNP measurement. Thus, BNP measurement gives
additional prognostic information and may improve
prediction of treatment response currently based on clin-
ical and Doppler sonographic (RI) variables. Third, in line
with the concept that renovascular hypertension causes an
elevation in BNP, we found that a decrease of BNP of more
than 20 pg ml1 1 day after successful intervention was also
significantly associated with BP improvement at the 6
month follow-up end point. Fourth, the highest sensitivity
and negative predictive value when using pre-intervention
BNP to predict BP improvement was found in selected
patients with refractory hypertension. This observation
confirms data from a recent pilot study by Silva et al.11
Fifth, increased cardiac stress prevails even after success-
ful correction of RAS in many patients. This phenomenon
may be explained by persistent irreversible cardiac damage
related to RAS or by cardiac disease independent of RAS.
Moreover, BNP levels tend to increase again from day 1e6
months after revascularisation. These data suggest that
some degree of progression of cardiac disease and cardiac
stress prevails even after correction of RAS.
The BP response rate in our study was comparable to that
observed in other large studies including unselected patients
with reported cure of hypertension in less than 10% and
improvement in 53%.4 Therefore, achieving optimal clinical
results for renal artery revascularisation is better predicated
with a judicious patient selection. Multiple parameters have
been evaluated for their utility in predicting which patients
Table 3 Diagnostic performance of BNP levels for the prediction of blood pressure improvement during follow up.
Sensitivity Specificity NPP PPV
Overall cohort (n Z 120)
BNP >50 pg/ml pre-intervention 79% 44% 63% 62%
BNP decrease >20 pg/ml 59% 61% 54% 65%
Patients with 70% atherosclerotic RAS (n Z 91)
BNP >50 pg/ml pre-intervention 83% 42% 69% 62%
BNP decrease >20 pg/ml 58% 66% 55% 64%
Patients with refractory hypertension (n Z 30)
BNP >50 pg/ml pre-intervention 100% 50% 100% 70%
BNP decrease >20 pg/ml 56% 54% 50% 60%
NPP indicates negative predictive value; PPV, positive predictive value; BNP, B-type natriuretic peptide; RAS, renal artery stenosis.
Natriuretic Peptide and Renal Artery Stenosis 605are most likely to benefit from PTRA in terms of BP control.
Partly in line with our study, clinical parameters such as
higher mean arterial BP at baseline, bilateral RAS, female
sex, fibromuscular dysplasia and lower intrarenal RI in the
segmental arteries measured by Doppler ultrasound have
been associated with higher rates of improvement in BP in
some but not all cohorts.17e19
Measurement of biomarkers, such as BNP, might improve
patient selection for renal artery revascularisation. BNP is
not only synthesised and released from left and right
ventricular myocytes in response to ventricular stretch and
neurohormonal activation, but is also released from
glomerular mesangial and epithelial cells.20 In the kidney, it
increases glomerular filtration and inhibits sodium reab-
sorption, causing natriuresis and diuresis and promotes
arterial and venous vasodilatation leading to reduced BP
and ventricular preload.6 Furthermore, BNP also has central
and peripheral sympathoinhibitory effects, and it also
inhibits the renineangiotensinealdosterone axis.21 This
regulation cascade incorporates several pathophysiological
consequences of RAS.1 Haemodynamically significant RAS
leads to reduced renal perfusion and consequently to
activation of the renineangiotensin system mediated by
angiotensinogen II, salt and water retention, and eventually
to BP elevation. In addition, activation of the sympathetic
nervous system may contribute also to hypertension in the
setting of RAS.22
Our findings are in coherence with a recent pilot study in
which BNP was investigated as a potential biomarker for
renovascular hypertension in 27 selected patients with
refractory hypertension and severe atherosclerotic RASTable 4 Multivariate analysis for the prediction of blood pressu
Age
Male sex
MAP pre-intervention, mmHg
eGFR < 60 ml/min/1.73 m2 pre-intervention
Intrarenal RI pre-intervention
BNP >50 pg/ml pre-intervention
BP indicates blood pressure; CI, confidence interval; MAP, mean arte
type natriuretic peptide.(70% diameter stenosis) referred for renal artery stent
placement.11 In this pilot study, using simple office BP
measurements, BP improved in 63% of patients at 3.5
months of follow-up and median BNP level fell significantly
1 day after successful stent procedure. Elevated BNP
>80 pg ml1 at baseline and a pronounced decrease in post-
treatment BNP correlated with improved BP control.
Compared to a sensitivity of 79% and specificity of 44% in
our study, elevated BNP before intervention was a stronger
predictor of hypertension improvement at follow-up in
their study (100% sensitivity, 50% specificity). Of note, in
a subset of patients with refractory hypertension, we found
the same sensitivity of 100% and specificity of 50%. As
identical assays for BNP were used in our study and in the
study by Silva and co-workers, the higher baseline BNP
levels observed in their cohort (median 187 pg ml1 vs.
97 pg ml1 in our overall cohort and 119 pg ml1 in patients
with refractory hypertension) suggest further differences in
baseline characteristics.11 Furthermore, we demonstrate
that applying BNP measurements to selected patients with
atherosclerotic RAS 70% or refractory hypertension who
benefit most from PTRA,2,17 rather than unselected
consecutive patients with hypertension and RAS, may
pronounce BNP elevations and therefore, also the accuracy
of using pre-intervention BNP to predict BP improvement.
Hence, particularly in this subgroup of patients, BNP seems
a new and interesting predictive marker of procedural
success.
Furthermore, lower pre-interventional BNP levels in our
study may explain the lower cut-off level of >50 pg ml1 for
predicting BP improvement. Cardiac structural diseasesre improvement during follow up.
Odds Ratio (95%CI) P-value
0.95 (0.89e0.99) 0.04
0.6 (0.2e1.5) 0.23
1.05 (1.01e1.20) 0.01
2.5 (0.8e7.2) 0.10
0.52 (0.001e232.2) 0.83
4.0 (1.2e13.2) 0.02
rial pressure; eGFR, estimated glomerular filtration rate; BNP, B-
606 D. Staub et al.with consecutive BNP elevations are also prevalent in
asymptomatic patients with essential arterial hyperten-
sion.23 Therefore, aetiologies for BNP elevation other than
renovascular hypertension may account for the low speci-
ficity found in both studies.24
Study limitations
Several limitations apply to this study. First, the exact
onset of arterial hypertension was unknown in the
majority of our patients. Therefore, we cannot examine
whether the BP response rate, BNP levels and the accu-
racy of BNP to predict BP response is influenced by the
duration of arterial hypertension. Second, in this
prospective, non-randomised cohort study, all of the
patients received percutaneous revascularisation of RAS
without inclusion of any control group. Therefore, our
results may not be applicable to patients undergoing
surgical correction of RAS,5 and we cannot preclude that
factors other than RAS may have contributed to the
elevation of BNP. However, median levels of BNP in our
cohort with RAS were elevated compared with a previously
published healthy control group and a patient cohort of
severe essential hypertension.9,15
Conclusion
We found that BNP levels were elevated in unselected
patients with hypertension and RAS referred for PTRA. BNP
levels decrease significantly after successful revascularisa-
tion. Elevated pre-interventional BNP level >50 pg ml1
and pronounced decrease of BNP >20 pg ml1 1 day after
successful intervention was associated with 24-h ambula-
tory BP improvement at 6 months follow-up. Therefore, the
use of pre-interventional BNP measurement may be helpful
to identify patients with RAS in whom PTRA will improve BP.
Further prospective interventional studies are needed to
determine whether its use will lead to a more targeted use
of PTRA.
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